Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.74 [0.57, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.50 [0.39, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 8.16 [3.74, 17.80] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
TRAE (any grade) | 0.76 [0.45, 1.26] | | < 1 | | 0% | 1 study (1/-) | 85.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.54 [0.32, 0.91] | | < 1 | | 0% | 1 study (1/-) | 98.9 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.92 [0.06, 57.48] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 1.65 [0.70, 3.87] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 2.73 [0.85, 8.76] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.05 [0.00, 0.88] | | < 1 | | 0% | 1 study (1/-) | 97.9 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.96 [0.06, 15.39] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.96 [0.06, 15.39] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 2.90 [0.30, 28.13] | | < 1 | | 0% | 1 study (1/-) | 18.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.28 [0.28, 5.81] | | < 1 | | 0% | 1 study (1/-) | 37.5 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.23 [0.05, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.85 [0.17, 86.06] | | < 1 | | 0% | 1 study (1/-) | 20.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.17] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.92 [0.06, 57.48] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.48 [0.02, 14.29] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.23 [0.03, 2.12] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.92 [0.06, 57.48] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.01, 5.29] | | < 1 | | 0% | 1 study (1/-) | 81.5 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 5.81 [0.29, 116.90] | | < 1 | | 0% | 1 study (1/-) | 12.8 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.23 [0.03, 2.12] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 1.92 [0.06, 57.48] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Vitiligo TRAE (grade 3-4) | 0.96 [0.02, 48.41] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.23 [0.03, 2.12] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |